Symbols / ATOS
ATOS Chart
About
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 36.25M |
| Enterprise Value | -15.59M | Income | -30.18M | Sales | — |
| Book/sh | 5.78 | Cash/sh | 6.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -0.97 | PEG | — |
| P/S | — | P/B | 0.73 | P/C | — |
| EV/EBITDA | 0.47 | EV/Sales | — | Quick Ratio | 6.30 |
| Current Ratio | 6.77 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.45 | EPS next Y | -4.33 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -29.87% |
| ROE | -48.89% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.61M |
| Shs Float | 8.61M | Short Float | 4.11% | Short Ratio | 2.17 |
| Short Interest | — | 52W High | 19.35 | 52W Low | 3.76 |
| Beta | 1.34 | Avg Volume | 139.97K | Volume | 95.38K |
| Target Price | $68.75 | Recom | Strong_buy | Prev Close | $3.96 |
| Price | $4.21 | Change | 6.31% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$68.75
Mean price target
2. Current target
$4.21
Latest analyst target
3. DCF / Fair value
$-34.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.21
Low
$10.00
High
$120.00
Mean
$68.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-06-06 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-06-05 | init | Craig-Hallum | — → Buy | $4 |
| 2025-04-21 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-12 | reit | HC Wainwright & Co. | Buy → Buy | — |
| 2024-12-09 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2024-11-13 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-05 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-11 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-06-20 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-06-06 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2024-05-14 | reit | Cantor Fitzgerald | — → Overweight | — |
- ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Stocktwits Mon, 02 Feb 2026 08
- Atos Stock Forecast 2026–2030 | Future Outlook - Capital.com ue, 27 Jan 2026 08
- Atossa Therapeutics Launches New $50 Million ATM Program - The Globe and Mail Sat, 21 Feb 2026 08
- Atos completes reverse stock split - Atos hu, 24 Apr 2025 07
- Is Atos (ENXTPA:ATO) Pricing In A Sustainable Recovery After Recent Share Surge? - Yahoo Finance Sun, 01 Feb 2026 08
- Atos Stock: Shares Drop to 35.50 Euros, Hitting Recent Lows - Idéal Investisseur ue, 24 Feb 2026 11
- Atossa eyes rare pediatric voucher in deadly muscle disease push - Stock Titan Wed, 11 Feb 2026 08
- Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals - PR Newswire Mon, 13 Oct 2025 07
- Assessing Atos (ENXTPA:ATO) Valuation After Recent Share Price Weakness - Yahoo Finance Wed, 18 Feb 2026 18
- Why Did ATOS Stock Jump 10% In Pre-Market Today? - Stocktwits Fri, 16 Jan 2026 08
- Breast cancer and rare disease therapy research earns major R&D award - Stock Titan Wed, 17 Dec 2025 08
- Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities - PR Newswire Mon, 06 Oct 2025 07
- Is Atos (ENXTPA:ATO) Pricing In A Turnaround After Sharp Recent Share Price Swings - Yahoo Finance Mon, 16 Feb 2026 08
- Atossa Therapeutics (Nasdaq: ATOS) lands U.S. patent with 100 (Z)-endoxifen claims - Stock Titan ue, 09 Dec 2025 08
- Has Atos Rebound and Turnaround Strategy in 2025 Created a Fresh Opportunity? - Yahoo Finance Fri, 12 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 325203 | — | — | Stock Award(Grant) at price 0.00 per share. | QUAY STEVEN C | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 1 | 11239 | 9887 | — | Purchase at price 0.88 per share. | QUAY STEVEN C | Chief Executive Officer | — | 2025-05-21 00:00:00 | D |
| 2 | 10000 | 7000 | — | Purchase at price 0.70 per share. | REMMEL H LAWRENCE | Director | — | 2025-03-26 00:00:00 | D |
| 3 | 25000 | 44250 | — | Purchase at price 1.77 per share. | FINN JONATHAN F. | Director | — | 2024-04-10 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -25.89M | -28.36M | -27.68M | -20.50M |
| TotalUnusualItems | -1.71M | -2.99M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -1.71M | -2.99M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -25.50M | -30.09M | -26.96M | -20.61M |
| ReconciledDepreciation | 17.00K | 23.00K | 8.00K | 23.00K |
| EBITDA | -27.60M | -31.35M | -27.68M | -20.50M |
| EBIT | -27.62M | -31.38M | -27.69M | -20.52M |
| NetInterestIncome | 4.05M | 4.34M | 877.00K | 6.00K |
| InterestIncome | 4.05M | 4.34M | 877.00K | 6.00K |
| NormalizedIncome | -23.79M | -27.10M | -26.96M | -20.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -25.50M | -30.09M | -26.96M | -20.61M |
| TotalExpenses | 27.62M | 31.38M | 27.69M | 20.52M |
| TotalOperatingIncomeAsReported | -27.62M | -31.38M | -27.69M | -20.52M |
| DilutedAverageShares | 8.39M | 8.41M | 8.44M | 7.80M |
| BasicAverageShares | 8.39M | 8.41M | 8.44M | 7.80M |
| DilutedEPS | -3.00 | -3.60 | -3.15 | -2.70 |
| BasicEPS | -3.00 | -3.60 | -3.15 | -2.70 |
| DilutedNIAvailtoComStockholders | -25.50M | -30.09M | -26.96M | -20.61M |
| NetIncomeCommonStockholders | -25.50M | -30.09M | -26.96M | -20.61M |
| NetIncome | -25.50M | -30.09M | -26.96M | -20.61M |
| NetIncomeIncludingNoncontrollingInterests | -25.50M | -30.09M | -26.96M | -20.61M |
| NetIncomeContinuousOperations | -25.50M | -30.09M | -26.96M | -20.61M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -25.50M | -30.09M | -26.96M | -20.61M |
| OtherIncomeExpense | -1.93M | -3.06M | -146.00K | -91.00K |
| OtherNonOperatingIncomeExpenses | -223.00K | -70.00K | -146.00K | -91.00K |
| SpecialIncomeCharges | -1.71M | -2.99M | 0.00 | |
| WriteOff | 1.71M | 2.99M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 4.05M | 4.34M | 877.00K | 6.00K |
| InterestIncomeNonOperating | 4.05M | 4.34M | 877.00K | 6.00K |
| OperatingIncome | -27.62M | -31.38M | -27.69M | -20.52M |
| OperatingExpense | 27.62M | 31.38M | 27.69M | 20.52M |
| ResearchAndDevelopment | 14.12M | 17.33M | 15.08M | 9.21M |
| SellingGeneralAndAdministration | 13.50M | 14.04M | 12.61M | 11.31M |
| GeneralAndAdministrativeExpense | 13.50M | 14.04M | 12.61M | 11.31M |
| OtherGandA | 13.50M | 14.04M | 12.61M | 11.31M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 88.00K | 88.00K | ||
| OrdinarySharesNumber | 8.61M | 8.35M | 8.44M | 8.44M |
| ShareIssued | 8.70M | 8.44M | 8.44M | 8.44M |
| TotalDebt | 0.00 | |||
| TangibleBookValue | 71.48M | 91.02M | 117.96M | 138.14M |
| InvestedCapital | 71.48M | 91.02M | 117.96M | 138.14M |
| WorkingCapital | 69.49M | 86.98M | 112.63M | 138.11M |
| NetTangibleAssets | 71.48M | 91.02M | 117.96M | 138.14M |
| CapitalLeaseObligations | 0.00 | |||
| CommonStockEquity | 71.48M | 91.02M | 117.96M | 138.14M |
| TotalCapitalization | 71.48M | 91.02M | 117.96M | 138.14M |
| TotalEquityGrossMinorityInterest | 71.48M | 91.02M | 117.96M | 138.14M |
| StockholdersEquity | 71.48M | 91.02M | 117.96M | 138.14M |
| TreasuryStock | 1.48M | 1.48M | 0.00 | |
| RetainedEarnings | -211.79M | -186.29M | -156.19M | -129.23M |
| AdditionalPaidInCapital | 261.26M | 255.99M | 251.37M | 244.58M |
| CapitalStock | 23.49M | 22.79M | 22.79M | 22.79M |
| CommonStock | 23.49M | 22.79M | 22.79M | 22.79M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 4.97M | 5.24M | 5.57M | 3.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 4.97M | 5.24M | 5.57M | 3.13M |
| OtherCurrentLiabilities | 1.51M | 1.80M | 19.00K | 21.00K |
| CurrentCapitalLeaseObligation | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.53M | 1.37M | 1.28M | 1.08M |
| PayablesAndAccruedExpenses | 1.93M | 2.06M | 4.26M | 2.03M |
| CurrentAccruedExpenses | 1.25M | 1.26M | 1.30M | 311.00K |
| Payables | 679.00K | 806.00K | 2.96M | 1.72M |
| AccountsPayable | 679.00K | 806.00K | 2.96M | 1.72M |
| TotalAssets | 76.44M | 96.25M | 123.53M | 141.26M |
| TotalNonCurrentAssets | 1.99M | 4.03M | 5.33M | 22.00K |
| OtherNonCurrentAssets | 1.99M | 2.32M | 635.00K | 22.00K |
| InvestmentsAndAdvances | 0.00 | 1.71M | 4.70M | 0.00 |
| InvestmentinFinancialAssets | 0.00 | 1.71M | 4.70M | 0.00 |
| AvailableForSaleSecurities | 1.71M | 4.70M | ||
| LongTermEquityInvestment | 4.70M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | |||
| NetPPE | 20.00K | |||
| AccumulatedDepreciation | -16.00K | |||
| GrossPPE | 36.00K | |||
| MachineryFurnitureEquipment | 36.00K | |||
| CurrentAssets | 74.46M | 92.22M | 118.20M | 141.24M |
| OtherCurrentAssets | 119.00K | 62.00K | 1.21M | 1.19M |
| RestrictedCash | 110.00K | 110.00K | 110.00K | 110.00K |
| PrepaidAssets | 3.14M | 3.59M | 5.25M | 2.49M |
| Receivables | 0.00 | 743.00K | 1.07M | |
| TaxesReceivable | 0.00 | 743.00K | 1.07M | |
| CashCashEquivalentsAndShortTermInvestments | 71.08M | 88.46M | 110.89M | 136.38M |
| CashAndCashEquivalents | 71.08M | 88.46M | 110.89M | 136.38M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -21.05M | -20.95M | -20.79M | -16.48M |
| RepurchaseOfCapitalStock | 0.00 | -1.48M | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 69.67M | ||
| CapitalExpenditure | -19.00K | -14.00K | -27.00K | -9.00K |
| EndCashPosition | 71.19M | 88.57M | 111.00M | 136.49M |
| BeginningCashPosition | 88.57M | 111.00M | 136.49M | 39.66M |
| ChangesInCash | -17.38M | -22.43M | -25.49M | 96.82M |
| FinancingCashFlow | 3.67M | -1.48M | 0.00 | 113.30M |
| CashFlowFromContinuingFinancingActivities | 3.67M | -1.48M | 0.00 | 113.30M |
| NetOtherFinancingCharges | -573.00K | |||
| ProceedsFromStockOptionExercised | 3.67M | 0.00 | 0.00 | 44.21M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | -1.48M | 0.00 | 69.67M |
| CommonStockPayments | 0.00 | -1.48M | 0.00 | |
| CommonStockIssuance | 0.00 | 69.67M | ||
| InvestingCashFlow | -19.00K | -14.00K | -4.73M | -9.00K |
| CashFlowFromContinuingInvestingActivities | -19.00K | -14.00K | -4.73M | -9.00K |
| NetInvestmentPurchaseAndSale | 0.00 | -4.70M | 0.00 | |
| PurchaseOfInvestment | 0.00 | -4.70M | 0.00 | |
| NetPPEPurchaseAndSale | -19.00K | -14.00K | -27.00K | -9.00K |
| PurchaseOfPPE | -19.00K | -14.00K | -27.00K | -9.00K |
| OperatingCashFlow | -21.03M | -20.94M | -20.76M | -16.47M |
| CashFlowFromContinuingOperatingActivities | -21.03M | -20.94M | -20.76M | -16.47M |
| ChangeInWorkingCapital | 448.00K | 1.52M | -599.00K | -1.16M |
| ChangeInOtherWorkingCapital | 208.00K | 129.00K | 341.00K | 220.00K |
| ChangeInOtherCurrentLiabilities | -296.00K | 1.78M | -2.00K | 17.00K |
| ChangeInOtherCurrentAssets | 331.00K | -1.70M | -597.00K | -521.00K |
| ChangeInPayablesAndAccruedExpense | -181.00K | -2.25M | 2.10M | 239.00K |
| ChangeInAccruedExpense | -54.00K | -86.00K | 855.00K | 111.00K |
| ChangeInPayable | -127.00K | -2.16M | 1.25M | 128.00K |
| ChangeInAccountPayable | -127.00K | -2.16M | 1.25M | 128.00K |
| ChangeInPrepaidAssets | 386.00K | 3.55M | -2.77M | -674.00K |
| ChangeInReceivables | 743.00K | 329.00K | -437.00K | |
| StockBasedCompensation | 2.29M | 4.62M | 6.79M | 5.27M |
| AssetImpairmentCharge | 1.71M | 2.99M | 0.00 | |
| DepreciationAmortizationDepletion | 17.00K | 23.00K | 8.00K | 23.00K |
| DepreciationAndAmortization | 17.00K | 23.00K | 8.00K | 23.00K |
| Depreciation | 17.00K | 23.00K | ||
| OperatingGainsLosses | 7.00K | 3.00K | ||
| NetIncomeFromContinuingOperations | -25.50M | -30.09M | -26.96M | -20.61M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ATOS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|